



Use of the ROSA™ robot in the context of a study* conducted in one of the leading centers for epilepsy in the United States

Montpellier, France, September 15th, 2014 – MEDTECH (Euronext, FR0010892950 – ROSA) specialized in the design, development and marketing of innovative robots for surgical assistance, has announced the publication of an American study conducted by the team at the Cleveland Clinic (Cleveland, OH, USA), one of the main centers for treating epilepsy in the United States and one of the first to use the ROSA™ robot.

Published in the leading scientific journal «Neurosurgery», this study on epilepsy surgery included a series of 200 patients.

The study indicates that this surgical technique is *«safe, reliable and efficient for treating epilepsy »* and that *«Combined with future technological developments in robotics,... it will fast becoming a definitive part of the epilepsy neurosurgeon's armamentarium for investing and treating patients with difficult-to-treat epilepsy»*.

« Our first experiences of using ROSA™ indicate that robotic assistance provides a potential platform to increase the safety and feasibility of SEEG procedures » said Doctor Jorge Gonzalez Martinez, member of the Cleveland Clinic team.

Medtech's President and Founder, Bertin Nahum says : *«This study, conducted by a leading center in the United States, highlights the added value of our ROSA™ robot devoted to minimally invasive epilepsy surgery »*.

Medtech shares can be integrated into PEA-PME accounts which benefit from the same tax advantages as a traditional equity savings plan.

-() Serletis D, Bulacio J, Bingaman W, Najm I, González-Martínez J. The stereotactic approach for mapping epileptic networks: a prospective study of 200 patients. J Neurosurg. 2014 Aug 22:1-8.*

About MEDTECH

Founded in 2002 by Bertin NAHUM and based near Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.



Press Release

In 2007, MEDTECH developed ROSA™, a state-of-the-art technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.

In 2013 Medtech received the « European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.

CONTACTS :

MEDTECH
Christophe Sibillin
Administrative and Financial Director
Tel : +33 (0)4 67 10 77 40

INVESTORS

Corinne Puissant
Tel : +33 (0)1 53 67 36 57
cpuissant@actus.fr

PRESS

Alexandra Prisa
Tel. : +33(0)1 53 67 35 79
aprisa@actus.fr